



# COVID-19

## Health Evidence Summary No.49

Kerry Millington & Samantha Reddin

Liverpool School of Tropical Medicine (LSTM) & Institute of Development Studies

29 May 2020

*This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government departments to the latest relevant evidence and discourse on COVID-19 to inform and support their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make original documents easily accessible to decision makers which, if relevant to them, they should go to before making decisions.*

### Clinical characteristics and management

Publication date	Title/URL	Journal/Article type	Summary
28.05.2020	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort	The Lancet HIV   Article	<ul style="list-style-type: none"> <li>• This observational prospective study characterises individuals aged <math>\geq 18</math>y with COVID-19 among a cohort of HIV-infected adults in Madrid. Included as information about incidence, clinical characteristics and outcomes of HIV-infected individuals with SARS-CoV-2 infection is scarce</li> <li>• As of 30 April 2020, 51 COVID-19 cases were diagnosed among a cohort of 2873 HIV-infected individuals</li> <li>• COVID-19 presented similar clinical, laboratory and radiological features in HIV-infected individuals compared with reports of the general population</li> <li>• Among HIV-infected individuals, lower CD4 cell counts affected disease severity and viral kinetics suggesting that those with low CD4 cell counts might have worse</li> </ul>

			<p>outcomes than individuals with restored immunity</p> <ul style="list-style-type: none"> <li>• HIV-infected individuals should receive the same treatment approach applied to the general population</li> </ul>
28.05.2020	COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study	The Lancet   Article	<ul style="list-style-type: none"> <li>• This prospective observational study in the UK describes the clinical and demographic characteristics and C19 outcomes in patients with cancer. Included as data from large multicentre studies to support the assumption that individuals with cancer are at increased risk of mortality from C19 are scarce</li> <li>• Authors did not identify evidence that cancer patients on cytotoxic chemotherapy or other anti-cancer treatments are at increased risk of mortality from C19, compared to those not on active treatment</li> <li>• Mortality from COVID-19 in cancer patients appears to be driven by age, sex and co-morbidities</li> </ul>
28.05.2020	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study	The Lancet   Article	<ul style="list-style-type: none"> <li>• This study characterises outcomes of a cohort of 928 patients aged <math>\geq 18</math>y with cancer and COVID-19 from the USA, Canada and Spain from the COVID-19 and Cancer Consortium (CCC19) database diverse in terms of age distribution, race and ethnicity, cancer status, and whether on anticancer treatment. Included as data on patients with COVID-19 who have cancer are lacking</li> <li>• Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer</li> </ul>

## Comments, Editorials, Opinions, Blogs, News

Publication date	Title/URL	Journal   Article type	Author(s)
30.05.2020	COVID-19 in Africa: no room for complacency	The Lancet   Editorial	
30.05.2020	Fears of “highly catastrophic” COVID-19 spread in Yemen	The Lancet   World Report	Sharmila Devi
29.05.2020	Covid-19 study on hydroxychloroquine use questioned by 120 researchers and medical professionals	The Guardian   News	Melissa Davey
29.05.2020	COVID-19 research in Africa	Science   Editorial	Linda-Gail Bekker Valerie Mizrahi
29.05.2020	Paying participants in COVID-19 trials	The Journal of Infectious Diseases   Review	Emily A. Largent Holly Fernandez Lynch
28.05.2020	The starting line for COVID-19 vaccine development	The Lancet   Comment	Nelson Lee Allison McGeer
28.05.2020	COVID-19 in people with HIV	The Lancet HIV   Comment	Zhe Xu Chao Zhang Fu-Sheng Wang
27.05.2020	A voice from the front line: reaching out of the box to engage private non-state healthcare actors in LMICs to combat COVID-19	Health Policy and Planning   Blog	Priya Balasubramaniam et al.
May 2020	First measles, now COVID-19 – are outbreaks finally moving the dial on vaccine hesitancy?	LSHTM   Feature	Jacqui Thornton

## Dashboards & Trackers

Cases & deaths: Global	Cases & deaths: Regional	Cases & deaths: Country	Living evidence & policy maps	Current research including trials	Diagnostics	Treatments	Vaccines
WHO sitreps	WHO Africa	Ghana	COVID-NMA	WHO	FIND SARS-CoV-2 Test Tracker	Global COVID-19 Clinical Trial Tracker	CEPI
WHO dashboard	African Arguments	Indonesia	EPPI Centre	WHO International Clinical Trials Registry Platform (ICTRP)	FIND SARS-CoV-2 Diagnostic tests: performance data	US NIH registered clinical trials	Vaccine Centre LSHTM
Johns Hopkins University	European CDC	Nigeria CDC	Norwegian Institute of Public Health	Cytel	Serology-based tests for COVID-19	Solidarity trial	COVID-19 Oxford Vaccine Trial
WEF		Sierra Leone	Oxford C19 Government Response Tracker (OxCGRT)	US NIH	Our World in Data: C19 Testing	COVID-19 Therapeutics Accelerator	
Our World in Data		Singapore	Our World in Data: C19 Policy responses	COVID-evidence			
Global 5050		UK	IFPRI COVID-19 Policy	Cochrane			

			Response Portal				
CEBM, University of Oxford		US		Clinicaltrials.gov			
Humanitarian Data Exchange				UKCDR			
Information is Beautiful							
LSHTM							
HealthMap (cases)							
The Commons Project							

## C19 Resource Hubs

Global	Regional & Country	Academic journals & Publishers	Institutes/Centres/Funders/Others	Health Topics	Social Sciences
WHO COVID-19 pandemic	Africa CDC	Annals of Internal Medicine	LSTM	Stop TB Partnership	SSHAP
WHO risk communication	African Union	BMJ	LSHTM		IDA

WHO Q&A	Nigeria CDC	Bulletin of the WHO	ICL MRC Centre for Global Infectious Disease Analysis	Global Menstrual Collective	Disability and Inclusion
WHO Global research	GeoPoll : SSA	Cambridge University Press	ODI	SLH: Handwashing in low resource settings	Coregroup IDDC
COVID-19 Solidarity Response Fund	Global Health Network Africa	Cell Press	Johns Hopkins University	RBM Partnership	Ethics, health systems & COVID-19
UN	African Academy of Sciences	Cochrane	Center for Global Development		Social Development Direct C19 blog series
UN Women	Africa Evidence Network	Elsevier	CMMID Repository		
UNOCHA	OCHA Southern and Eastern Africa COVID-19 Digest	JAMA Network	Norwegian Institute of Public Health		
UNHCR		The Lancet	Oxford Centre for Evidence-based Medicine		
UNICEF		medRxiv and bioRxiv (Preprints)	HEART		

UNESCO		NEJM	UKRI		
UN WFP		Oxford University Press	Evidence Aid		
GOARN		PLoS	NIH		
EPI-WIN		SAGE journals	IFPRI Resources and Analyses of C19 Impact		
World Bank		Science	Prevent Epidemics		
Our World in Data		Springer Nature			
COVID-19 Narratives by David Nabarro		SSRN (Preprints)			
Reliefweb		Wiley			
Humanitarian OpenStreetMap Team					
Global Partnership for Sustainable Development Data					
WorldPop					
Flowminder					
COVID-END					

Premise COVID-19 Global Impact Study					
---	--	--	--	--	--

## Online learning & events

Date	Title/URL	Online learning/event	Duration	Lead
May 28 09:30 am to 11:00 am EDT	<a href="#">Virtual Event - No backsliding: How can we re-orient food systems and health systems to protect nutrition and healthy diets in the context of COVID-19?</a>	Virtual event	1.5 hours	IFPRI
Available now	<a href="#">COVID-19: Effective Nursing in Times of Crisis</a>	Online course	2 weeks – 2 hours per week	Johns Hopkins School of Nursing
04.06.2020 12pm ET	<a href="#">CGD Conversations on COVID-19 and Development: John Nkengasong</a>	Event		CGD
Available now	<a href="#">WHO Academy and WHO Info mobile applications</a>	Mobile app		WHO
Available now	<a href="#">COVID-19: Pandemics, Modelling and Policy</a>	Online learning	2 weeks   2 hours weekly study	FutureLearn UNESCO UNITWIN Complex Systems Digital Campus/Open University
11.5.2020	<a href="#">COVID-19 Contact Tracing course</a>	Online learning	5 hours	Johns Hopkins Bloomberg School of Health

7-28 May 2020	Virtual Evidence Weeks	5 sessions	1h 30	International Initiative for Impact Evaluation (3ie)
Tuesdays at 1700 CEST (Geneva time) & Thursdays 0830 CEST (Geneva time)	COVID-19 Open online brief with Dr David Nabarro	Event	1h	4SD
30.04.2020	Professor Chris Whitty's Gresham lecture on COVID-19	Event	1h 20	Gresham College
Available now	Emerging respiratory viruses, including COVID-19: methods for detection, prevention, response and control	Online learning	3 hours	WHO
Available now	Responding to COVID-19: Real-time training for the coronavirus disease outbreak	Online learning	Multiple self-paced course	WHO
25 May 2020	COVID-19: Tackling the Novel Coronavirus	Online learning	3 weeks   4 hours weekly study	FutureLearn LSHTM/UK PHRST
Available online now without mentors. Updated version will commence early June 2020	COVID-19 Diagnostics and Testing	Online learning	3 weeks   3 hours weekly study	FutureLearn FIND/LSHTM/ASLM

6 April 2020	<b>COVID-19 Critical Care: Understanding and Application</b>	Online learning	5 weeks   1 hour weekly study	FutureLearn University of Edinburgh & Royal College of Physicians of Edinburgh
Available now	<b>COVID-19 supporting online courses</b>	Online learning	Multiple self-paced course	BMJ Learning

## Suggested citation

Millington, K.A. and Reddin, S. (2020). *COVID-19 Health Evidence Summary No.49*. K4D Evidence Summary. Brighton, UK: Institute of Development Studies.

## Rapid review methodology

The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are included. Articles related to tackling the secondary impacts on other sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance.

The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter.

## About this report

This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make original documents easily accessible to decision makers which, if relevant to them, they should go to before making decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. K4D services are provided by a consortium of leading organisations working in international development, led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and Conflict Response Institute (HCRI).

This evidence summary was prepared for the UK Government’s Department for International Development (DFID) and its partners in support of pro-poor programmes. It is licensed for non-commercial purposes only. K4D cannot be held responsible for errors, omissions or any consequences arising from the use of information contained in this health evidence summary. Any views and opinions expressed do not necessarily reflect those of DFID, K4D or any other contributing organisation.

© DFID - Crown copyright 2020.

